Veklury® Demonstrated Efficacy and Safety in Vulnerable Patient Populations

Gilead Sciences, Inc. today announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases.

For example, a Phase 3 clinical study demonstrated that Veklury® (remdesivir) was generally well tolerated in people with moderate to severe renal impairment.

Additional data includes a retrospective real-world study that demonstrated that Veklury treatment is associated with a lower risk of death from COVID-19 for people with cancer.

A separate real-world analysis demonstrated that Veklury is also associated with reduced hospital readmission risk in immunocompromised patients hospitalized with COVID-19.

"The breadth of clinical and real-world evidence data presented at ECCMID further support the strong efficacy and safety profile of Veklury," said Frank Duff, MD, Senior Vice President, Virology Therapeutic Area Head, Gilead Sciences, in a press release on April 16, 2023.

"Since the beginning of the (COVID-19) pandemic, Veklury has played a critical role in the treatment of hospitalized patients with COVID-19."

"The real-world data further demonstrates its role in reducing mortality and hospital readmission rates in vulnerable patient populations, including people living with cancer and other immunosuppressed conditions."

Additionally, results from a Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of obeldesivir, previously known as GS-5245, a novel investigational oral compound developed by Gilead for the treatment of SARS-CoV-2 infection, showed obeldesivir reaches expected therapeutic plasma concentrations for the treatment of COVID-19.